Although the expression of β-catenin has been described to be increased in EGFR-mutant NSCLC,14 an additional potential increase in Wnt pathway activity because of pathogenic CTNNB1 mutations had no impact on patient outcome. This evidence concerns the gene EGFR and non-small cell lung carcinoma.